Financial Performance - The company's revenue for Q3 2024 reached ¥819,349,868.90, an increase of 6.55% compared to the same period last year[4] - Net profit attributable to shareholders was ¥90,656,869.27, representing a significant increase of 52.42% year-on-year[4] - The net profit after deducting non-recurring gains and losses was ¥94,023,769.83, up 57.57% from the previous year[4] - The company's basic earnings per share for Q3 2024 was ¥0.15, a 50.00% increase year-on-year[4] - Net profit for Q3 2024 was approximately ¥223.51 million, a decrease of 8.06% compared to ¥243.20 million in Q3 2023[21] - Operating profit for Q3 2024 was approximately ¥302.12 million, a decrease of 2.67% from ¥309.26 million in Q3 2023[21] - The company reported a total comprehensive income of approximately ¥225.35 million for Q3 2024, compared to ¥339.64 million in Q3 2023[22] - Basic and diluted earnings per share for Q3 2024 were both ¥0.36, down from ¥0.40 in the same period last year[22] Assets and Liabilities - Total assets as of September 30, 2024, amounted to ¥5,865,981,600.14, reflecting a growth of 9.58% compared to the end of the previous year[4] - Total liabilities increased to ¥1,826,131,226.28 from ¥1,416,901,298.61, showing a significant rise of 28.88%[18] - The company's total equity reached ¥4,039,850,373.86, up from ¥3,936,490,744.21, indicating a growth of 2.87%[19] - The company’s total assets decreased by approximately 3.5% year-over-year, reflecting a strategic focus on asset management[21] Cash Flow - Cash flow from operating activities for the year-to-date period decreased by 45.93%, totaling ¥280,815,136.57[4] - Cash flow from operating activities generated a net amount of approximately ¥280.82 million, down from ¥519.40 million in the previous year[23] - Cash and cash equivalents at the end of Q3 2024 totaled approximately ¥859.21 million, an increase from ¥578.87 million at the end of Q3 2023[24] - The company's cash and cash equivalents increased to ¥859,214,794.32 from ¥605,084,126.50, representing a growth of 42.06%[16] - The company experienced a significant increase in cash flow from investing activities, with a net cash outflow of approximately ¥251.94 million compared to ¥304.19 million in Q3 2023[24] Shareholder Information - The total number of common shareholders at the end of the reporting period is 43,753[10] - Xiamen Jindawei Investment Co., Ltd. holds 34.71% of shares, totaling 211,712,732 shares, with 92,191,500 shares pledged[10] - The second-largest shareholder, Zhongmu Industrial Co., Ltd., holds 18.68% of shares, totaling 113,927,593 shares[10] - The third-largest shareholder, Xiamen Special Development Co., Ltd., holds 4.88% of shares, totaling 29,762,564 shares[10] - The top ten unrestricted shareholders include Hong Kong Central Clearing Limited, holding 1.37% with 8,341,532 shares[11] - The total number of shares held by the top ten unrestricted shareholders is 211,712,732 shares[12] - The company has no known related party relationships among the top shareholders[13] - The top ten shareholders have seen changes in their holdings due to securities lending activities[15] - The company has a total of 28,500,000 shares held through credit securities accounts[13] Operational Metrics - Total operating revenue for the period reached ¥2,342,754,762.46, a slight increase of 0.95% compared to ¥2,320,697,373.46 in the previous period[20] - Total operating costs amounted to ¥2,052,347,262.47, up from ¥2,022,820,179.65, reflecting a year-over-year increase of 1.16%[20] - Accounts receivable rose to ¥393,532,741.21, up from ¥353,216,974.94, indicating an increase of 11.41%[16] - Inventory levels increased to ¥840,942,280.08 from ¥715,824,665.55, marking a rise of 17.5%[16] - Non-current assets totaled ¥3,457,029,505.16, compared to ¥3,308,617,181.60, reflecting an increase of 4.49%[17] - Research and development expenses for the period were ¥50,181,138.55, slightly down from ¥50,906,479.82 in the previous period[20] Future Outlook - The company plans to issue convertible bonds, pending approval from the China Securities Regulatory Commission[15] - The company plans to expand its market presence and invest in new product development to drive future growth[21] - The company reported a net profit margin improvement, with net profit increasing due to effective cost management strategies[20] Financing Activities - The company reported a significant increase in accounts receivable financing, which rose by 489.51% to ¥2,884,000.00[8] - The company's short-term borrowings increased by 361.06%, reaching ¥267,625,421.96, primarily due to an increase in one-year bank loans[8] - The company received government subsidies amounting to ¥3,390,085.93 during the reporting period, contributing to its financial performance[6]

证券时报e公司讯，NMN概念走强，截至发稿，金达威、雅本化学涨停，尔康制药、兄弟科技、德展健 康等涨幅居前。 消息面上，据中国科学院天津工业生物所消息，该所通过开发从头合成途径提高烟酰胺单核苷酸 （NMN）产量，实现超过100倍的NMN产量提升。 ...

Investment Rating - The report initiates coverage with a "Buy" rating for the company, setting a target price of 18.19 CNY based on a relative valuation method with a PEG of 0.9 for 2024 [4][6]. Core Insights - The company, Xiamen Kingdawei Group Co., Ltd., is a leading global supplier of coenzyme Q10 and health supplement raw materials, established in November 1997 and listed on the Shenzhen Stock Exchange in October 2011 [1][13]. - The global health supplement market is expanding, driven by increased health awareness, an aging population, and a growing demand from younger demographics [2][4]. - The company possesses significant competitive advantages in both B2B and B2C sectors due to its comprehensive technology platform and established brand influence in mature overseas markets [3][4]. Financial Performance - In H1 2024, the company reported revenue of 1.523 billion CNY, a decrease of 1.82% year-on-year, and a net profit attributable to the parent company of 130 million CNY, down 29.31% [1][21]. - For the full year 2023, the company achieved revenue of 3.103 billion CNY, a year-on-year increase of 3.10%, with a net profit of 277 million CNY, up 7.50% [1][21]. - The gross margin for 2023 was 37.33%, a decrease of 3.16 percentage points year-on-year, while the net profit margin was 8.92%, an increase of 0.38 percentage points [1][21]. Market Dynamics - The VDS (Vitamin Dietary Supplements) market is experiencing continuous expansion, with key drivers including rising household income, increased health consciousness, and a growing elderly population [2][4]. - The company is well-positioned to benefit from the ongoing growth in the health supplement sector, particularly in coenzyme Q10 and vitamins, which are expected to maintain a growth trend [4][5]. Competitive Advantages - The company has established a "National Enterprise Technology Center" and a large-scale enzyme library platform, which supports its competitive edge in both raw material supply and finished health products [3][4]. - The company is actively expanding its new business ventures, which are expected to provide additional growth opportunities, alongside the coenzyme Q10 expansion project aimed at increasing market share [3][4].

金达威：取得发明专利证书 财联社10月21日电，金达威公告，公司及全资子公司厦门金达威维生素有 限公司近日收到国家知识产权局颁发的1件发明专利证书。 发明名称：固定化N-羟基邻苯二甲酰亚胺树脂及其制备方法和应用及7-酮胆固醇乙酸酯的制备方法。 专利申请日为2021年12月22日，专利权期限为二十年。 查看公告原文 ...

发明名称：固定化 N-羟基邻苯二甲酰亚胺树脂及其制备方法和应用及 7-酮 胆固醇乙酸酯的制备方法 专利号：ZL 2021 1 1582053.5 专利申请日：2021 年 12 月 22 日 证券代码：002626 证券简称：金达威 公告编号：2024-086 厦门金达威集团股份有限公司 关于取得发明专利证书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 厦门金达威集团股份有限公司（以下简称公司）及公司全资子公司厦门金达 威维生素有限公司，近日收到国家知识产权局颁发的 1 件发明专利证书，具体情 况如下： 专利权人：厦门金达威维生素有限公司；厦门金达威集团股份有限公司 专利权期限：二十年 证书号：第 7450912 号 授权公告日：2024 年 10 月 18 日 本发明属于有机合成领域，涉及一种固定化 N-羟基邻苯二甲酰亚胺树脂及 其制备方法和应用及 7-酮胆固醇乙酸酯的制备方法。采用以上方法所得固定化 N-羟基邻苯二甲酰亚胺树脂可循环使用，并且将其与弱碱性树脂和分子筛配合使 用，能够使得 7-酮胆固醇乙酸酯的收率达到 70％以上，产物含量达到 90 ...

厦门金达威集团股份有限公司 关于控股股东部分股份质押的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 厦门金达威集团股份有限公司（以下简称公司）近日收到公司控股股东厦门 金达威投资有限公司（以下简称金达威投资）将其所持有的公司部分股票进行股 票质押的通知，现将有关事项公告如下： 证券代码：002626 证券简称：金达威 公告编号：2024-087 截至公告披露日，上述股东所持质押股份情况如下： 股东 名称 持股数量 持股比 例 本次质押 前质押股 份数量 本次质押 后质押股 份数量 占其所 持股份 比例 占公司 总股本 比例 已质押股 份情况 未质押股 份情况 已质 押股 份限 售和 占 已 质 押 股 未质 押股 份限 售和 占 未 质 押 股 | | | | | | | | 冻结 | 份 | 冻结 | 份 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | | | 数量 | 比 | 数量 | 比 | | | | | | | | | | 例 ...

广发证券股份有限公司 关于 厦门金达威集团股份有限公司 向不特定对象发行可转换公司债券 行 广发证券股份有限公司 GF SECURITIES CO.,LTD. 二零二四年十月 厦门金达威集团股份有限公司 上市保荐书 声 明 广发证券股份有限公司（以下简称"广发证券"、"保荐人"或"保荐机 构"）及具体负责本次证券发行上市项目的保荐代表人已根据《中华人民共和 国公司法》《中华人民共和国证券法》等法律、法规和中国证监会及深圳证券 交易所的有关规定，诚实守信，勤勉尽责，严格按照依法制订的业务规则和行 业自律规范出具本上市保荐书，并保证本上市保荐书的真实、准确、完整。 之 上市保荐书 3-3-2 厦门金达威集团股份有限公司 上市保荐书 第一节 本次证券发行基本情况 一、发行人基本情况 （一）发行人基本信息 | 公司名称（中文） | 厦门金达威集团股份有限公司 | | | | --- | --- | --- | --- | | 公司名称（英文） | Xiamen Kingdomway Group Company | | | | 上市交易所 | 深圳证券交易所 | | | | 股票简称及代码 | 金达威（002626.S ...

证券代码：002626 证券简称：金达威 公告编号：2024-085 关于向不特定对象发行可转换公司债券的募集说明书等申请文 件更新的提示性公告 公司本次发行事项尚需履行中国证券监督管理委员会（以下简称"中国证监 会"）注册程序，公司将在收到中国证监会作出的予以注册或不予注册的决定文 件后另行公告。公司将根据该事项的进展情况及时履行信息披露义务，敬请广大 投资者谨慎决策，注意投资风险。 特此公告。 厦门金达威集团股份有限公司 董 事 会 二〇二四年十月十五日 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 厦门金达威集团股份有限公司（以下简称"公司"）向不特定对象发行可转 换公司债券（以下简称"本次发行"）的申请已于 2024 年 9 月 27 日获深圳证券 交易所上市审核委员会审核通过。具体内容详见公司于 2024 年 9 月 28 日在巨潮 资讯网（http://www.cninfo.com.cn）披露的《关于公司向不特定对象发行可转换 公司债券申请获得深圳证券交易所上市审核委员会审核通过的公告》（公告编号： 2024-083）。 近日公司会同相关中介机构 ...

广发证券股份有限公司 关于 厦门金达威集团股份有限公司 向不特定对象发行可转换公司债券 之 发行保荐书 j 广发证券股份有限公司 GF SECURITIES CO.,LTD. 二零二四年十月 厦门金达威集团股份有限公司 发行保荐书 声 明 广发证券股份有限公司（以下简称"广发证券"、"保荐人"或"保荐机构"） 及具体负责本次证券发行项目的保荐代表人已根据《中华人民共和国公司法》 《中华人民共和国证券法》等有关法律、法规和中国证监会的有关规定，诚实 守信，勤勉尽责，严格按照依法制订的业务规则、行业执业规范和道德准则出 具本发行保荐书，并保证本发行保荐书及其附件的真实、准确和完整。 如无特别说明，本发行保荐书中所有简称和释义，均与《厦门金达威集团 股份有限公司向不特定对象发行可转换公司债券募集说明书》一致。 3-1-1 厦门金达威集团股份有限公司 发行保荐书 目 录 | 声 明 | | --- | | 日 求… | | 第一节 本次证券发行基本情况 | | 一、本次证券发行的保荐机构. | | 二、本次证券发行的保荐机构工作人员情况 | | 三、发行人基本情况. | | 四、本次证券发行的保荐机构与发行人的关联关 ...

股票简称：金达威 股票代码：002626 厦门金达威集团股份有限公司 （住所：福建省厦门市海沧新阳工业区） 向不特定对象发行可转换公司债券 募集说明书 （注册稿） 保荐人（主承销商） 二〇二四年十月 厦门金达威集团股份有限公司 募集说明书 发行人声明 中国证监会、交易所对本次发行所作的任何决定或意见，均不表明其对申 请文件及所披露信息的真实性、准确性、完整性作出保证，也不表明其对发行 人的盈利能力、投资价值或者对投资者的收益作出实质性判断或保证。任何与 之相反的声明均属虚假不实陈述。 根据《证券法》的规定，证券依法发行后，发行人经营与收益的变化，由 发行人自行负责。投资者自主判断发行人的投资价值，自主作出投资决策，自 行承担证券依法发行后因发行人经营与收益变化或者证券价格变动引致的投资 风险。 公司提请投资者仔细阅读本募集说明书"风险因素"全文，并特别注意以 下风险： （一）安全生产和安全事故风险 公司生产过程中使用的部分化学原料为易燃、易爆物品，若在安全管理的 某个环节发生疏忽或员工操作不当、设备老化失修，均可能发生失火、爆炸等 安全事故，影响公司的生产经营，造成一定程度的经济损失。 2024 年 1 月， ...